(Q46214562)

20 December 2017

title

Comparison of ImmunoCyt, UroVysion, and urine cytology in detection of recurrent urothelial carcinoma: a "split-sample" study (English)

1 reference

20 December 2017

1 reference

Peggy S Sullivan

1

1 reference

20 December 2017

Farzad Nooraie

2

1 reference

20 December 2017

Hope Sanchez

3

1 reference

20 December 2017

Sharon Hirschowitz

4

1 reference

20 December 2017

Mary Levin

5

1 reference

20 December 2017

P Nagesh Rao

6

1 reference

20 December 2017

Jianyu Rao

7

1 reference

20 December 2017

language of work or name

English

0 references

publication date

1 June 2009

1 reference

20 December 2017

number of pages

7

1 reference

inferred from page(s)

published in

Cancer

1 reference

20 December 2017

volume

117

1 reference

20 December 2017

issue

3

1 reference

20 December 2017

page(s)

167-173

1 reference

20 December 2017

The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20026

21 January 2018

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20026

7 January 2021

Clinical utility of a multiprobe FISH assay in voided urine specimens for the detection of bladder cancer and its recurrences, compared with urinary cytology

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20026

7 January 2021

Multicolor fluorescence in situ hybridization (M-FISH) on cells from urine for the detection of bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20026

7 January 2021

uCyt+ test: alternative to cystoscopy for less-invasive follow-up of patients with low risk of urothelial carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20026

7 January 2021

The UroVysion fluorescence in situ hybridization assay is an effective tool for monitoring recurrence of bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20026

7 January 2021

Comparison of the ImmunoCyt test and urinary cytology with other urine tests in the detection and surveillance of bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20026

7 January 2021

Liquid-based cytology as a tool for the performance of uCyt+ and Urovysion Multicolour-FISH in the detection of urothelial carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20026

7 January 2021

ImmunoCyt/uCyt+ improves the sensitivity of urine cytology in patients followed for urothelial carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20026

7 January 2021

Role of uCyt+ in the detection and surveillance of urothelial carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20026

7 January 2021

Immunocyt: a new tool for detecting transitional cell cancer of the urinary tract

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20026

7 January 2021

Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20026

7 January 2021

UroVysion compared with cytology and quantitative cytology in the surveillance of non-muscle-invasive bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20026

7 January 2021

Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20026

7 January 2021

The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20026

7 January 2021

Performance of urine test in patients monitored for recurrence of bladder cancer: a multicenter study in the United States

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20026

7 January 2021

Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20026

7 January 2021

uCyt+/ImmunoCyt in the detection of recurrent urothelial carcinoma: an update on 1991 analyses

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20026

7 January 2021

Improved detection of urothelial carcinomas with fluorescence immunocytochemistry (uCyt+ assay) and urinary cytology: results of a French Prospective Multicenter Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20026

7 January 2021

The value of the UroVysion assay for surveillance of non-muscle-invasive bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20026

7 January 2021

ImmunoCyt a useful method in the follow-up protocol for patients with urinary bladder carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20026

7 January 2021

Fluorescence in situ hybridization for detecting transitional cell carcinoma: implications for clinical practice

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20026

7 January 2021

Identifiers

DOI

10.1002/CNCY.20026

1 reference

20 December 2017

PubMed ID

19365828

1 reference

20 December 2017